关键词: 子宫颈肿瘤, 新辅助化疗, 同步放化疗, 手术, 化疗方案

Abstract: Concurrent chemoradiation is the first choice of treatment for locally advanced cervical cancer. However，in a radiation resource-limited setting or as a part of efforts to avoid radiation-induced adverse effects，neoadjuvant chemotherapy followed by radical hysterectomy has been used as an alternative in many countries and regions. Multiple clinical trials have confirmed the feasibility and safety of neoadjuvant chemotherapy with cisplatin or carboplatin plus paclitaxel. Compared with primary radical surgery，preoperative neoadjuvant chemotherapy can improve resection rate，reduce postoperative complications，and decrease the demand for adjuvant radiotherapy，while the long-term survival benefits are still controversial. Compared with concurrent chemoradiation，neoadjuvant chemotherapy followed by radical surgery is associated with a shorter progression-free survival，but it does not compromise the overall survival，and the spectrum of toxic effects varies between these two treatment strategies. In conclusion，neoadjuvant chemotherapy has strengths and limitations in treatment for locally advanced cervical cancer，and it is necessary to balance its advantages and disadvantages and make personalized decisions. Hopefully，efforts to optimize chemotherapy regimens and predict responsiveness to chemotherapy are able to improve the chemotherapy response rate in the near future，conferring more benefits for cervical cancer patients.

Key words: cervical neoplasm, neoadjuvant chemotherapy, concurrent chemoradiation, surgery, chemotherapy regimen